| Title: |
Correlation of a commercial platform’s results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors |
| Authors: |
Slotkin, Rebecca; Kyriakides, Tassos C.; Kundu, Anupam; Stack, Gary; Sutton, Richard E.; Gupta, Shaili |
| Contributors: |
Harapan, Harapan; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Fogarty International Center of the National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health |
| Source: |
PLOS ONE ; volume 18, issue 8, page e0289713 ; ISSN 1932-6203 |
| Publisher Information: |
Public Library of Science (PLoS) |
| Publication Year: |
2023 |
| Collection: |
PLOS Publications (via CrossRef) |
| Description: |
Introduction The objective of this study was to describe the correlation between the commercially available assay for anti-S1/RBD IgG and protective serum neutralizing antibodies (nAb) against SARS-CoV-2 in an adult population after SARS-CoV-2 vaccination, and determine if clinical variables impact this correlation. Methods We measured IgG anti-S1/RBD using the IgG-II CMIA assay and nAb IC 50 values against SARS-CoV-2 WA-1 in sera serially collected post-mRNA vaccination in veterans and healthcare workers of the Veterans Affairs Connecticut Healthcare System (VACHS) between December 2020 and January 2022. The correlation between IgG and IC 50 was measured using Pearson correlation. Clinical variables (age, sex, race, ethnicity, prior COVID infection defined by RT-PCR, history of malignancy, estimated glomerular filtration rate (GFR calculated using CKD-EPI equation) were collected by manual chart review. The impact of these clinical variables on the IgG-nAb correlation was analyzed first with univariable regression. Variables with a significance of p < 0.15 were analyzed with forward stepwise regression analysis. Results From 127 sera samples in 100 unique subjects (age 20–93 years; mean 63.83; SD 15.63; 29% female; 67% White), we found a robust correlation between IgG anti-S1/RBD and nAb IC 50 ( R 2 = 0.83, R 2 adj = 0.70, p < 0.0001). Race, ethnicity, and a history of malignancy were not significant on univariable analysis. GFR (p < 0.05) and prior COVID infection (p < 0.001) had a significant impact on the correlation between IgG anti-S1/RBD and nAb IC 50 . Age (p = 0.06) and sex (p = 0.07) trended towards significance on univariable analysis, but were not significant on multivariable regression. Conclusions There was a strong correlation between IgG anti-S1/RBD and nAb IC 50 after SARS-CoV-2 vaccination. Clinical comorbidities, such as prior COVID infection and renal function, impacted this correlation. These results may assist the prediction of post-vaccination immune protection in clinical ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1371/journal.pone.0289713 |
| Availability: |
https://doi.org/10.1371/journal.pone.0289713; https://dx.plos.org/10.1371/journal.pone.0289713 |
| Rights: |
https://creativecommons.org/publicdomain/zero/1.0/ |
| Accession Number: |
edsbas.C7F5C41A |
| Database: |
BASE |